Biotts S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2018-07-05
Share capital
1,248,676.00 PLN
Average employment (people)
12 (2025)
Activity description

Biotts is a biotech company specializing in transdermal drug delivery systems and its proprietary MTC-Y™ technology, which enables needle-free delivery of larger molecules such as peptides and proteins. It develops its own transdermal drug products and collaborates with the pharmaceutical industry, while also providing GMP-compliant R&D and laboratory services for pharmaceutical, biotechnology, cosmetics, and dietary supplement companies.

Registered address
ul. Wrocławska 44C, 55-040 Bielany Wrocławskie, Poland
Website
Email
Social media

Financials

Revenue history (in k)

Financial insight

  • The statement flags a going concern risk. Sprawozdanie finansowe Spółki zostało sporządzone przy założeniu kontynuowania działalności gospodarczej przez co najmniej 12 miesięcy po dniu bilansowym. Biorąc pod uwagę aktualną sytuację Spółki, Zarząd Spółki identyfikuje okoliczności, które mogą powodować niepewności co do kontynuacji działalności. Spółka BIOTTS S.A. znajduje się nadal w fazie intensywnego rozwoju kluczowych produktów o istotnym potencjale i nie realizuje jeszcze powtarzalnych przychodów, sytuacja nie odbiega od lat ubiegłych. W 2025 roku Spółka rozpoczęła świadczenie usług badawczo-rozwojowych dla firm zewnętrznych, wykorzystując posiadane doświadczenie, zaplecze laboratoryjne oraz kapitał ludzki. W 2025 roku z tego typu działalności udało się uzyskać 298 tysięcy złotych przychodów netto. W 2026 roku spółka planuje zintensyfikować działania sprzedażowe i zwiększyć przychody w tym obszarze działalności. W roku zakończonym dnia 31 grudnia 2025 roku Spółka odnotowała stratę w kwocie 3 909 tysięcy zł. Natomiast bilans sporządzony na dzień 31 grudnia 2025 roku pokazuje dodatnią wartość kapitału obrotowego, w kwocie 679 tysięcy zł. Zgodnie z prognozami na 2026 r. Spółka zakłada zwiększenie wielkości sprzedaży, przy czym plan finansowy na 2026 r. zakłada stratę na podstawowej działalności gospodarczej – niemniej jednak kapitał własny na koniec roku 2026 nadal pozostanie na poziomie dodatnim. Spółka swoją działalność w 2025 r. i w latach wcześniejszych w głównym stopniu finansowała z wpływów z emisji akcji i dot

From the notes

Contingent liabilitiesYes
Shares in other companies
  • NGD Sp. z o.o. 100%
  • Biotts Inc. 100%

Filing timeliness

2 of 6 financial statements were filed late (the longest delay 92 days for 2025). All were audited by a statutory auditor.

  • 202515/10/2026
  • 202418/07/2025
  • 202320/06/2024
  • 202229/06/2023
  • 202127/06/2022
  • 202001/10/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 44%
Top 46%
City · Bielany Wrocławskie148 / 232
Top 64%
Voivodeship · Dolnośląskie13,900 / 23,831
Top 58%
Country · Poland175,566 / 297,069
Top 59%

Results vs industry

Revenue
This companyUSD 159.26kMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD -981.64kMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 704.02kMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 1.03mMedianUSD 281.58kAverageUSD 8.35m

News

De-risking the clinical pathway: Biotts provides translational validation for the $13B chronic wound care market

De-risking the clinical pathway: Biotts provides translational validation for the $13B chronic wound care market

The global chronic wound care market is currently valued at over $13 billion, driven by an urgent clinical need for more effective treatments for diabetic foot ulcers, pressure sores, and hard-to-heal surgical wounds. Despite the massive commercial potential, pharmaceutical pipelines in this space historically face high attrition rates, largely due to poor translational models that fail to accurately predict human clinical outcomes.

Data in Frontiers in Pharmacology shows Biotts' proprietary platform significantly outpaces standard antibiotic therapy in chronic wound care

Data in Frontiers in Pharmacology shows Biotts' proprietary platform significantly outpaces standard antibiotic therapy in chronic wound care

Biotts has achieved a significant scientific and commercial milestone with the publication of new peer-reviewed data in the prestigious journal Frontiers in Pharmacology.

Biotts' New Study on Transdermal Lidocaine and Tetracaine in Pharmaceutics

Biotts' New Study on Transdermal Lidocaine and Tetracaine in Pharmaceutics

Biotts publishes peer-reviewed research in Pharmaceutics (MDPI) validating MTC-Y™ technology for transdermal delivery of lidocaine and tetracaine.

Biotts Granted US Patent for MTC-Y Transdermal Carrier Technology

Biotts Granted US Patent for MTC-Y Transdermal Carrier Technology

Biotts has been granted US Patent No. 12,478,679 B2 for its MTC-Y transdermal carrier technology. The patent was issued by the USPTO on 25 November 2025.

Biotts at BioJapan 2025 – Bringing Polish Transdermal Innovation to Asia

Biotts at BioJapan 2025 – Bringing Polish Transdermal Innovation to Asia

Biotts represented Polish transdermal innovation at BioJapan 2025 in Yokohama, Japan - Asia's premier bio-industry partnering event. Read about our experience.

Offer

Websites

  • biotts.comThe global leader in transdermal drug delivery systems
    WordPressGoogle AnalyticsGoogle Tag ManagerYoast SEOApache

Public procurement

3 tenders recorded as contractor, with a total value of $95,400.

SubjectAmount
Research service involving in vivo testing of the elimination of Staphylococcus aureus from animal skin using the enzybiotic Aurezyna R, and research service involving the development of a measurement method...
$45,048
Development of a formulation prototype
$49,855
U/12/2025/B Organization and delivery of off-site training courses for the Faculty of Chemistry and Pharmacy
$497

Trademarks

The company holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2020.

MarkNumberClassesStatusProtected until
BIOTTS (word)Z.5227181, 3, 5, 42, 44Protected Dec 29, 2030
MarkProtected until
BIOTTS (word)Dec 29, 2030

Authorized Representatives

Beata Turlejska age 48 – Vice President of the Management Board
Paweł Czesław Biernat age 51 – President of the Management Board

Manner of representation

Each member of the management board is entitled to represent the company independently.

Supervisory board

Tomasz Grzegorz Sobkowicz age 36 – Supervisory Board Member
Karol Hop age 38 – Supervisory Board Member
Radosław Zagrodnik age 51 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2018-03-02.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 36,858

MSiG notices

Publication dateEvent
Aug 21, 2026Commercial Companies Code notice
Jul 1, 2026Shareholders' meeting convened
Jun 13, 2019Commercial Companies Code notice

Public aid

10 public aid cases recorded, with a total value of $4,589,696.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
–
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
–
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
–

European Funds

ProjectEU co-financing
Preparation by Biotts S.A. of a Eurogrant project planned for implementation under the EIC Pre-accelerator - Widening programme (HORIZON-WIDERA-2025-02)
$17,431

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Scope Fluidics S.A.
Medicofarma Biotech S.A.
F1 Pharma S.A.
Genelytica sp. z o.o.
TCI sp. z o.o.
Nanosanguis S.A.
Countess Laboratories sp. z o.o.
Cofactor sp. z o.o.
Personather sp. z o.o.
Meditransfer Centrum Transferu Technologii Iitd sp. z o.o.

Change history

DateEvent
2026-10-12Share capital increase
2026-03-13Share capital increase
2025-08-12Share capital increase
2025-05-23Share capital increase
2024-12-23Share capital increase

FAQ

Last updated: 2026-10-21